Eli Lilly has struck a deal to sell a UK R&D campus to UCB. The deal positions UCB to turn the former Lilly neuroscience center into one of its three global R&D hubs. UCB will make the 47 acre site one of three global R&D hubs, the others being in the U.S. and Belgium, and thereby deliver on its 2018 commitment to establish the UK as a focal point of its activities. Source: Fierce Biotech, 16/10/2020